Suppr超能文献

来自乳酸菌的细菌素及其他控制艰难梭菌感染和相关胃肠道结肠炎的替代方法

Bacteriocins From LAB and Other Alternative Approaches for the Control of and Related Gastrointestinal Colitis.

作者信息

Todorov Svetoslav D, Kang Hye-Ji, Ivanova Iskra V, Holzapfel Wilhelm H

机构信息

Advanced Green Energy and Environment Institute (AGEE), Handong Global University, Pohang, South Korea.

HEM Inc., Handong Global University, Pohang, South Korea.

出版信息

Front Bioeng Biotechnol. 2020 Sep 11;8:581778. doi: 10.3389/fbioe.2020.581778. eCollection 2020.

Abstract

The gut microbiome is considered as a promising target for future non-conventional therapeutic treatment of inflammatory and infectious diseases. The search for appropriate safe and beneficial (lactic acid bacterial and other) putative probiotic strains and/or their antimicrobial metabolites represents a challenging approach for combating several problematic and emerging infections. The process of selecting suitable strains, especially of lactic acid bacteria (LAB) with superior properties, has been accelerated and intensified during the past two decades, also thanks to recent developments in lab techniques. Currently, special focus is on the potential of antimicrobial metabolites produced by some LAB strains and their application as active therapeutic agents. The vision is to develop a scientific basis for 'biotherapeutics' as alternative to conventional approaches in both human and veterinary medicine. Consequently, innovative and promising applications of LAB to the therapeutic practice are presently emerging. An overview of the existing literature indicates that some antimicrobial metabolites such as bacteriocins, widely produced by different bacterial species including LAB, are promising biotherapeutic agents for controlling infections caused by potential pathogens, such as and . Non-conventional, safe and well designed therapeutic treatments may contribute to the improvement of gut dysbiotic conditions. Thereby gut homeostasis can be restored and inflammatory conditions such as gastrointestinal colitis ameliorated. Combining the knowledge on the production, characterization and application of bacteriocins from probiotic LAB, together with their antibacterial properties, appears to be a promising and novel approach in biotherapy. In this overview, different scenarios for the control of spp. by application of bacteriocins as therapeutic agents, also in synergistic combination with antibiotics, will be discussed.

摘要

肠道微生物群被认为是未来用于炎症性和感染性疾病非常规治疗的一个有前景的靶点。寻找合适的安全有益(乳酸菌及其他)的假定益生菌菌株和/或其抗菌代谢产物,是对抗几种有问题的和新出现的感染的一种具有挑战性的方法。在过去二十年里,由于实验室技术的最新发展,选择合适菌株,特别是具有优良特性的乳酸菌(LAB)的过程得到了加速和强化。目前,特别关注的是一些LAB菌株产生的抗菌代谢产物的潜力及其作为活性治疗剂的应用。其愿景是为人医和兽医学开发一种作为传统方法替代方案的“生物疗法”的科学基础。因此,LAB在治疗实践中的创新和有前景的应用目前正在出现。现有文献综述表明,一些抗菌代谢产物,如由包括LAB在内的不同细菌物种广泛产生的细菌素,是控制由潜在病原体如[具体病原体1]和[具体病原体2]引起的感染的有前景的生物治疗剂。非常规、安全且设计良好的治疗方法可能有助于改善肠道生态失调状况。从而可以恢复肠道内环境稳定,并改善诸如胃肠结肠炎等炎症状况。将关于益生菌LAB产生的细菌素的生产、特性和应用的知识与其抗菌特性相结合,似乎是生物治疗中一种有前景的新方法。在本综述中,将讨论应用细菌素作为治疗剂,以及与抗生素协同联合使用来控制[具体病原体属]的不同方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d30/7517946/2851745ff6cf/fbioe-08-581778-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验